BrightInsight vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 73)
BrightInsight logo

BrightInsight

LeaderHealthcare

Regulated Digital Health Platform

BrightInsight is the leading global regulated digital health platform for biopharma and medtech; raised $166M total (Series C $101M led by General Catalyst in 2021); supports SaMD, connected devices, and disease management programs.

AI VisibilityBeta
Overall Score
B73
Category Rank
#90 of 596
AI Consensus
93%
Trend
stable
Per Platform
ChatGPT
72
Perplexity
73
Gemini
74

About

BrightInsight is a digital health infrastructure company that provides the leading global regulated platform for biopharma and medtech companies building Software as a Medical Device (SaMD) and connected health programs. Founded in 2017 by Kal Patel, a former Bristol-Myers Squibb executive, BrightInsight is headquartered in San Jose, California. The company's platform captures, transmits, and analyzes data from FDA-regulated and CE-marked medical devices, combination products, digital therapeutics, and companion apps — all while maintaining compliance with HITRUST, GDPR, FDA 21 CFR Part 11, IEC 62304, and other regulatory frameworks. This regulated-by-design infrastructure layer eliminates the need for biopharma and medtech companies to build compliant digital health backends from scratch.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

73
Overall Score
93
#90
Category Rank
#1
93
AI Consensus
80
stable
Trend
stable
72
ChatGPT
94
73
Perplexity
89
74
Gemini
94
71
Claude
92
73
Grok
98

Key Details

Category
Regulated Digital Health Platform
Enterprise
Tier
Leader
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.